Ariana Pharma

The companies will combine Nabsys' technology to identify the structural variants with Ariana's clinical data analysis tools.

NEW YORK (GenomeWeb News) – The WIN Consortium, an International personalized medicine initiative, will use €3 million ($3.9 million) in funding from the European Union to launch an effort to provide tailored cancer treatment regimens to patients based on genetic analysis, the consortium said tod

NEW YORK (GenomeWeb News) – The French government has provided €13.4 million ($17.4 million) to fund the Innovative MODels Initiative (IMODI), a partnership aimed at facilitating the development of new cancer treatments.

NEW YORK (GenomeWeb News) – Ariana Pharma announced today an exclusive distribution deal with CTC Laboratory Systems covering Japan.

Ariana Pharma, a provider of an association rules-based clinical data analysis technology, has tapped Mariana Kuras to serve as its chief technology officer.

The goal of the project, called Hepachronix, is to gain a better understanding of how liver fibrosis progresses from early, mild stage to debilitating diseases such as cirrhosis and hepatoma carcinoma.

Ariana Pharma announced this week that the FDA will use its KEM Biomarker technology to "systematically identify potential genomic 'fingerprints' and develop recommendations for the analysis of genomic data prior to submission of biomarker signatures."

The FDA will use Ariana Pharma's biomarker data mining technology to review and analyze data submitted through a voluntary data submission program.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.